FUTURE THERAPIES, TESTED TODAY
AI-TWIN is an innovative biotech startup advancing personalized medicine through breakthrough discoveries in biomedical and clinical research.
By integrating human biology with cutting-edge microfabrication and organ-on-chip technologies, AI-TWIN is developing next-generation platforms for more precise and predictive therapies.
REDEFINING RESEARCH WITH HUMAN BIOLOGY ON A CHIP
AI-TWIN is pioneering the future of personalized medicine with its unique Biological Twin + Digital Twin approach.
We create patient-specific 3D multi-tissue models using the patient’s own cells, true Biological Twin, paired with AI-driven Digital Twin that interpret data and predict therapeutic response.
The result is a powerful platform ideal for:
- Accurate disease modeling
- Predictive testing of therapies
- Personalized treatment guidance
AI-TWIN is transforming how research translates into real impact for patients.
FUTURE PERSPECTIVES
AI-TWIN is developing OoCs in the form of microfluidic devices for 3D cell cultivation, capable of reproducing the tissue microenvironment thanks to the engineering of geometric, mechanical and biochemical factors and therefore mimicking the structures and functions of human organs in vivo.
By utilizing each patient’s cells and integrating biological twins with digital twins, AI-TWIN enables a personalized medicine approach in treatment discovery and adjustment.
Support preclinical studies using readily available tissue microchips and not animal/in vitro models
Evaluate drug candidates rapidly on a large scale
Obtain a high quantity of real time data
Create a digital twin adaptable to other conditions
INNOVATION
At the core of AI-TWIN’s innovation is the convergence of Biological and Digital Twins, creating a powerful framework for generating predictive, patient-specific data.This enables the development of Clinical Trials on Chips, a new paradigm for evaluating drug efficacy and safety with unprecedented speed, precision, and ethical standards.
This breakthrough approach is set to reshape the pharmaceutical landscape, unlocking truly personalized clinical trials and accelerating the future of drug development.
PARTNERS
FUTURE THERAPIES, TESTED TODAY
AI-TWIN is an innovative biotech startup advancing personalized medicine through breakthrough discoveries in biomedical and clinical research.
By integrating human biology with cutting-edge microfabrication and organ-on-chip technologies, AI-TWIN is developing next-generation platforms for more precise and predictive therapies.
REDEFINING RESEARCH WITH
HUMAN BIOLOGY ON A CHIP
AI-TWIN is pioneering the future of personalized medicine with its unique Biological Twin + Digital Twin approach.
We create patient-specific 3D multi-tissue models using the patient’s own cells, true Biological Twin, paired with AI-driven Digital Twin that interpret data and predict therapeutic response.
The result is a powerful platform ideal for:
- Accurate disease modeling
- Predictive testing of therapies
- Personalized treatment guidance
AI-TWIN is transforming how research translates into real impact for patients.
FUTURE PERSPECTIVES
Our research represents a turning point for clinical practice, the pharmaceutical industry, and academia.
We aim at developing a new generation of in vitro systems, the next-generation personalized organ on chip (OoC).
They are created with the use of a microfluidic device, starting from patient biopsies, useful for advanced research on new treatments and permitting patient-specific clinical trials-on-chip.
Support preclinical studies using readily available tissue microchips and not animal/in vitro models
Lowering costs for drug screenings
Translational research to identify new therapeutic markers
Improved patient care
and reduced side effects
INNOVATION
At the core of AI-TWIN’s innovation is the convergence of Biological and Digital Twins, creating a powerful framework for generating predictive, patient-specific data.This enables the development of Clinical Trials on Chips, a new paradigm for evaluating drug efficacy and safety with unprecedented speed, precision, and ethical standards.
This breakthrough approach is set to reshape the pharmaceutical landscape, unlocking truly personalized clinical trials and accelerating the future of drug development.
PARTNERS
Ai-Twin srl
Sede legale e operativa
C.so Trieste, 15/A – 28100 Novara (NO)
C.F./P.IVA 02722210032
SDI SUBM70N
USEFUL LINKS
WHERE TO FIND US